NCT02142868 is a clinical trial of Palbociclib in Advanced Breast Cancer (Female), sponsored by Pfizer.

Who is sponsoring NCT02142868?

NCT02142868 is sponsored by Pfizer.

What drugs are being tested in NCT02142868?

Interventions in NCT02142868: Palbociclib, Letrozole.

What condition does NCT02142868 study?

NCT02142868 studies Advanced Breast Cancer (Female).

Is NCT02142868 still recruiting?

NCT02142868 is currently no longer available. Last updated 21 December 2018.

Last reviewed 2018-12-21 · How we verify

NCT02142868

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

NO LONGER AVAILABLE Last updated 21 December 2018

What this trial tests

trial testing Palbociclib in Advanced Breast Cancer (Female). No longer available.

Quick facts

Lead sponsor	Pfizer
Status	NO LONGER AVAILABLE
Study type	EXPANDED_ACCESS
Sites	55 locations across Canada, United States

Drugs / interventions tested

Palbociclib (Palbociclib) — full drug profile →
Letrozole — full drug profile →

Conditions studied

Advanced Breast Cancer (Female) — all drugs for Advanced Breast Cancer (Female) →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, female only, with Advanced Breast Cancer (Female). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To provide access to palbociclib to post-menopausal women with HR-positive, HER2-negative advanced breast cancer who are deemed appropriate for letrozole therapy (Canada: first-line patients only).

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Cyclin D1, cancer progression, and opportunities in cancer treatment.
Qie S, Diehl JA. · · 2016 · cited 527× · PMID 27695879 · DOI 10.1007/s00109-016-1475-3
CDK4 and CDK6 kinases: From basic science to cancer therapy.
Fassl A, Geng Y, Sicinski P. · · 2022 · cited 351× · PMID 35025636 · DOI 10.1126/science.abc1495
Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.
Gyanchandani R, Kota KJ, Jonnalagadda AR, Minteer T, et al · · 2017 · cited 38× · PMID 28978004 · DOI 10.18632/oncotarget.11383
Progress with palbociclib in breast cancer: latest evidence and clinical considerations.
Rocca A, Schirone A, Maltoni R, Bravaccini S, et al · · 2017 · cited 37× · PMID 28203301 · DOI 10.1177/1758834016677961
Early access provision: Awareness, educational needs and opportunities to improve oncology patients' access to care.
Krendyukov A, Singhvi S, Green-Morrison Y, Zabransky M. · · 2022 · cited 3× · PMID 36387084 · DOI 10.3389/fonc.2022.714516

Verify or expand the search:

Other trials of Palbociclib

Trials testing the same drug.

NCT07492641 — BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer · Phase 3 · not yet recruiting
NCT07405164 — Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) · Phase 3 · recruiting
NCT07347600 — A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
NCT06997029 — A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors · Phase 1 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02142868 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 21 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02142868.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing